Therapeutics

Phone: (650) 368 6983
info@airmid.com


Target Portfolio >>AIRMIDs Therapeutics
Two of AIRMID’s drug candidates
	Most potent and selective oral and topical Kv1.3 blocker known (KD = 2nM). Excellent safety profile. Patent protected. Derivative of a natural compound from the plant, Ruta graveolens.

	Highly potent and most selective Kv1.3 blocker known (KD = 70pM). Excellent safety profile. Injectable. Patent protected. Derivative of a natural compound from the sea anemone, Stichodactyla helianthus.
By starting from natural sources of potential autoimmune drugs and applying creative methods of derivatization, AIRMID’s founders have succeeded in developing therapeutically promising Kv1.3 blockers even as several large pharmaceutical companies have failed.

October 2006

AIRMID receives Series A
financing from Biotechnology
Value Fund.

more...